Bethesda, Maryland 20892

  • Brain and Central Nervous System Tumors


RATIONALE: Drugs used in chemotherapy such as talampanel use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well talampanel works in treating patients with recurrent, progressive high-grade glioma.

Study summary:

OBJECTIVES: - Determine the efficacy of talampanel, in terms of 6-month progression-free survival, in patients with recurrent high-grade gliomas. - Determine, preliminarily, the toxic effects of this drug in these patients. - Determine, preliminarily, the quality of life of patients treated with this drug. - Determine the pharmacokinetics of this drug in patients who are and who are not receiving enzyme-inducing antiepileptic drugs. OUTLINE: Patients are stratified according to type of glioma (anaplastic astrocytoma vs glioblastoma multiforme). Patients in each stratum are assigned to 1 of 3 treatment groups according to concurrent enzyme-inducing antiepileptic drug use (yes, no, or valproic acid). Patients in each group receive different doses of oral talampanel 3 times daily on days 1-42. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline, every 3 weeks during the first course, every 6 weeks before all subsequent courses, and then within 2 weeks of study completion. Patients are followed within 2 weeks. PROJECTED ACCRUAL: A total of 91 patients (50 with anaplastic astrocytoma and 41 with glioblastoma multiforme) will be accrued for this study within 1 year.


DISEASE CHARACTERISTICS: - Histologically confirmed high-grade glioma, including any of the following: - Glioblastoma multiforme - Anaplastic astrocytoma - Anaplastic oligodendroglioma - Anaplastic mixed oligoastrocytoma - Malignant astrocytoma not otherwise specified - Patients with clinical and radiographic diagnosis of brain stem glioma are also eligible - Evidence of tumor progression by MRI or CT scan - Scan must be performed while patient is on a stable steroid dose for at least 5 days - Must have failed prior radiotherapy - Residual disease after prior resection of recurrent or progressive tumor is allowed PATIENT CHARACTERISTICS: Age - 18 and over Performance status - Karnofsky 60-100% Life expectancy - More than 8 weeks Hematopoietic - Absolute neutrophil count greater than 1,500/mm^3 - Platelet count at least 100,000/mm^3 (transfusion independent) - Hemoglobin at least 10 g/dL (transfusion allowed) Hepatic - Bilirubin less than 2 times upper limit of normal (ULN) - SGOT less than 2 times ULN - No significant active hepatic disease Renal - Creatinine less than 1.5 mg/dL OR - Creatinine clearance at least 60 mL/min - No significant active renal disease Cardiac - No significant active cardiac disease Other - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use 2 effective methods of contraception during and for 2 months after study participation - Able to swallow whole capsules - No active infection requiring IV antibiotics - No significant active psychiatric disease that would preclude use of the study drug - No other significant uncontrolled medical illness that would preclude study participation - No other active life-threatening malignancy PRIOR CONCURRENT THERAPY: Biologic therapy - At least 1 week since prior interferon or thalidomide - No concurrent anticancer immunotherapy Chemotherapy - At least 2 weeks since prior vincristine - At least 3 weeks since prior procarbazine - At least 6 weeks since prior nitrosoureas - No other concurrent anticancer chemotherapy Endocrine therapy - See Disease Characteristics - At least 1 week since prior tamoxifen - Concurrent steroids for the control of increased intracranial pressure allowed Radiotherapy - See Disease Characteristics - At least 4 weeks since prior radiotherapy - No concurrent anticancer radiotherapy Surgery - See Disease Characteristics - Prior recent resection of recurrent or progressive disease allowed Other - Recovered from all prior therapy - At least 1 week since prior noncytotoxic agents (e.g., isotretinoin), except for radiosensitizers - At least 4 weeks since prior investigational agents - At least 4 weeks since prior cytotoxic therapy - No other concurrent investigational agents



Primary Contact:

Study Chair
Howard A. Fine, MD
NCI - Neuro-Oncology Branch

Backup Contact:


Location Contact:

Bethesda, Maryland 20892
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: March 30, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.